Examining the relationship between chronic kidney disease, dyslipidaemia, and dysglycemia: a prospective study


  • Anirban Ghosh Department of Medicine, College of Medicine and Jawaharlal Nehru Memorial Hospital, Kalyani, West Bengal, India
  • Anirban Dutta Department of Medicine, College of Medicine and Jawaharlal Nehru Memorial Hospital, Kalyani, West Bengal, India
  • Arpita Kayet Department of Anaesthesia, ESI Hospital, Kalyani, West Bengal, India




Chronic kidney disease, Dyslipidemia, Dysglycemia


Background: Chronic kidney disease (CKD) results in profound lipid disorders, which stem largely from dysregulation of high-density lipoproteins (HDL) and triglyceride-rich lipoprotein metabolism. Objectives were to evaluate the correlation between chronic kidney disease, dyslipidaemia and dysglycemia.

Methods: In-patient and outpatient department (OPD) of department of medicine, COM and JNM Hospital, Kalyani. Cases are defined as patients (>20 years of age) with a diagnosis of CKD (non-oedematous). The controls are defined as age and gender-matched patients (>20 years) attending medicine OPD/indoor without diagnosis of CKD.

Results: Among the CKD cases, 30 individuals were diagnosed as overtly diabetic, whereas in the control group, 22 participants had fasting blood sugar (FBS) levels equal to or exceeding 126 mg/dl. The mean FBS was 111 mg/dl (standard deviation (SD) 44 mg/dl) in the CKD group and 91 mg/dl (SD 31 mg/dl) in the control group. The difference in FBS levels between the CKD patients' group and the control group was statistically significant (p value=0.001).

Conclusions: Hyperglycaemia is also significantly associated with CKD in form of increased fasting blood sugar (47% among cases as compared to 30% in control) and increased post-prandial blood sugar (49% in cases as compared to 36% in controls). Dyslipidaemia occurs in CKD cases (39% among CKD cases and in 24% of controls) in the form of increased triglycerides (TG), LDL and low HDL.


National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(1):S1-2.

McCullough PA, Verril TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med. 2010;122(2):25-34.

Chmielewski M, Carrero JJ, Nordfors L, Lindholm B, Stenvinkel P. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol. 2008;21:635-44.

Nam KH, Chang TI, Joo YS, Kim J, Lee S, Lee C, et al. Association between serum high-density lipoprotein cholesterol levels and progression of chronic kidney disease: results from the KNOW-CKD. J Am Heart Assoc. 2019;8:e011162.

Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18:29-40.

Gall M-A, Rossing P, Skøtt P, Damsbo P, Vaag A, Bech K, et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1991;34:655-61.

Parving H-H. Diabetic nephropathy: Prevention and treatment. Kidney Int. 2001;60:2041-55.

Tonelli M, Bohm C, Pandeya S, Gill J, Gill J, Levin A, et al. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484-9.

Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125(3):217-30.

Sakharova OV, Taal MW, Brenner BM. Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor. Curr Opin Nephrol Hypertens. 2001;10:727-38.

Rhee CM, Kovesdy CP, Ravel VA, Streja E, Brunelli SM, Soohoo M, et al. Association of glycemic status during progression of chronic kidney disease with early dialysis mortality in patients with diabetes. Diabetes Care. 2017;40:1050-7.

Dautin G, Soltani Z, Ducloux D, Gautier T, Pais de Barros JP, Gambert P, et al. Hemodialysis reduces plasma apolipoprotein C I concentration making VLDL a better substrate for lipo¬protein lipase. Kidney Int. 2007;72:871-8.

Mesquita J, Varela A, Medina JL. Dyslipidemia in renal disease: causes, consequences and treatment. Endocrinol Nutr. 2010;57:440-8.

Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18(9):2600-8.

Lee C, Park JT, Chang TI, Kang EW, Nam KH, Joo YS, et al. Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: results from the KNOWCKD. Nutr Metab Cardiovasc Dis. 2022;32:410-9.

Palazhy S, Viswanathan V. Lipid Abnormalities in Type 2 Diabetes Mellitus Patients with Overt Nephropathy. Diabetes Metab J. 2017;41(2):128-34.

Sujatha NR, Kuldeep GB. Lipid Profile in Chronic Renal Failure Patients on Haemodialysis. J Med - Clin Res Rev. 2023;7(6):1-4.

Mikolasevic I, Žutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35-45.

Suh SH, Oh TR, Choi HS, Kim CS, Bae EH, Ma SK, et al. Non-high-density lipoprotein cholesterol and cardiovascular outcomes in chronic kidney disease: results from KNOW-CKD Study. Nutrients. 2022;14:3792.




How to Cite

Ghosh, A., Dutta, A., & Kayet, A. (2024). Examining the relationship between chronic kidney disease, dyslipidaemia, and dysglycemia: a prospective study. International Journal of Research in Medical Sciences, 12(6), 1926–1930. https://doi.org/10.18203/2320-6012.ijrms20241535



Original Research Articles